SCYNEXIS, INC. (SCYX) - 10-K Filing Summary
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2025. SCYNEXIS, Inc. is a biotechnology company focused on developing "fungerps," a novel class of antifungal agents. The company's lead approved product, BREXAFEMME (ibrexafungerp), was licensed to GlaxoSmithKline (GSK) in May 2023 for commercialization outside of Greater China and Russia. The company's primary development focus is now on SCY-247, a second-generation fungerp in clinical trials for invasive candidiasis (IC) and other fungal infections.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $20.6 million | $3.7 million |
| Net Loss | $(8.6) million | $(21.3) million |
| Operating Expenses | $36.7 million | $40.9 million |
| Cash, Cash Equivalents, and Investments | $56.3 million | $75.1 million |
| Accumulated Deficit | $(385.1) million | $(376.5) million |
| Net Cash Used in Operating Activities | $(5.3) million | $(24.0) million |
Note: Revenue in 2025 includes a $17.2 million cumulative catch-up recognition related to the termination of the MARIO study with GSK.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 450% to $20.6 million, driven primarily by a $17.2 million revenue recognition adjustment following the termination of the Phase 3 MARIO study with GSK. Product revenue was minimal ($1.4 million) due to a prior period recall adjustment.
- Reduced Net Loss: Net loss improved significantly to $8.6 million from $21.3 million, aided by the revenue recognition and a $5.8 million gain from the fair value adjustment of warrant liabilities.
- Expense Reduction: Research and Development (R&D) expenses decreased by 15.6% to $22.3 million, largely due to a $3.8 million reduction in chemistry, manufacturing, and controls (CMC) costs associated with drug product manufacturing.
- Debt Repayment: The company repaid $14.0 million in convertible debt that matured in March 2025.
Guidance, Outlook, and Risks
- SCY-247 Development: The company completed Phase 1 oral studies for SCY-247, showing a favorable safety profile. A Phase 1 intravenous study was initiated in Q1 2026, with a Phase 2 proof-of-concept study planned for 2026.
- GSK Collaboration: The MARIO study was terminated in October 2025. SCYNEXIS received a one-time payment of $24.8 million from GSK. GSK retains rights to commercialize BREXAFEMME for vulvovaginal candidiasis (VVC) and plans to relaunch the product in the U.S. in 2026.
- Liquidity: Management believes current capital resources ($56.3 million) are sufficient to fund operations for at least 12 months. However, the company expects to continue incurring losses and will require additional financing for SCY-247 development.
- Nasdaq Compliance: The company received a notice in June 2025 regarding non-compliance with the $1.00 minimum bid price rule. An extension was granted until June 15, 2026, to regain compliance, potentially through a reverse stock split.
- Risks: Key risks include the uncertainty of SCY-247 regulatory approval, dependence on third-party partners (GSK, Hansoh, R-Pharm) for commercialization, and the need for substantial additional capital.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $56.3 million cash balance against the projected costs of the SCY-247 Phase 2 study and ongoing operations.
- Nasdaq Listing Status: Monitor the company's progress toward meeting the $1.00 minimum bid price requirement by June 15, 2026, to avoid delisting.
- GSK Relaunch Timeline: Confirm GSK's ability to initiate FDA interactions and relaunch BREXAFEMME in 2026 as anticipated.
- SCY-247 Clinical Data: Review upcoming data releases from the Phase 1 IV study and the planned Phase 2 IC study for safety and efficacy signals.
- Future Financing: Assess the terms and dilution impact of any upcoming equity or debt offerings required to fund development.